Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05885360
Other study ID # STUDY00005472
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date January 20, 2023
Est. completion date December 2024

Study information

Verified date October 2023
Source Georgetown University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an investigator-initiated trial. In this 6-month open label, single arm, exploratory pilot study, the investigator intends to enroll a pilot sample of 25 patients with Parkinson's disease who are being started on the novel FDA approved medication "Istradefylline'' as an add on therapy for management of their motor symptoms (based on the judgment of the movement disorders specialist, if patients are in sub-optimal management of their symptoms on maximum tolerable dose of their dopaminergic medications). The investigator will evaluate their motor symptoms before starting the new medication, including their MDS-UPDRS total and MDS-UPDRS-III scores.


Description:

In this 6-month open label, single arm, exploratory pilot study, the investigator intends to enroll a pilot sample of 25 patients with Parkinson's disease who are being started on the novel FDA approved medication "Istradefylline'' as an add on therapy for management of their motor symptoms (based on the judgment of the movement disorders specialist, if patients are in suboptimal management of their symptoms on maximum tolerable dose of their dopaminergic medications). The investigator will evaluate their motor symptoms before starting the new medication, including their MDS-UPDRS total and MDS-UPDRS-III scores. Based on data from an early experience limited data set within our clinical practice of patients taking Istradefylline, the investigator noted improvement in motor symptoms on PDRS-III. The investigator evaluated the degree of tremor with a tremor quantifying software before and after 8 weeks of therapy. Tremor amplitude, frequency and severity improved in the first two patients based on said parameters. Secondary analysis in week 24 will include all aforementioned assessments. The investigator will compare their score and results before and after the medication. The therapeutic intervention will consist of evaluating the effect of the addition of Istradefylline 40 mg daily (after two weeks of Istradefylline 20 mg daily) in patients already on levodopa and other anti- parkinsonian treatments. Patients will be screened based on inclusion and exclusion criteria. Enrolled patients will need to be on a stable regimen of all their concomitant medications for at least 30 days prior to baseline visit. All PD concomitant medications are allowable. Participants must also have a MOCA (Montreal Cognitive Assessment) of 22 or greater, and the absence of a diagnosis of dementia. Tremor score will be clinically defined by the presence of a sum score of at least 8 of 32 of the MDS-UPDRS tremor items 16, 20, and 21 (referred to as tremor score). The generation of this sum score is based on the validity of the MDS-UPDRS regarding tremor, 19 and the clinical experience, that the MDS-UPDRS tremor items reflect different but similarly important aspects of Parkinsonian tremor, including the impairment of activities of daily living by tremor.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 27
Est. completion date December 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - · Written informed consent - Capable of providing informed consent and complying with study procedures - Clinical diagnosis of Parkinson's disease according to the United Kingdom Brain Bank criteria which includes the following. - Bradykinesia - At least one of the following: - Muscular righty - 4-6 Hz rest tremor - Postural instability not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction - Must be on a stable regimen of all current concomitant medication, including carbidopa-levodopa for at least 30 days prior to baseline visit - Participants also have a MOCA (Montreal Cognitive Assessment) score of 22 or greater - Study subjects are willing to present for all study visits and take medication. - The MDS-UPDRS I-III will be used to assess a baseline tremor score Exclusion Criteria: - · Diagnosis of dementia - defined by NIH as the loss of cognitive functioning such as thinking, remembering, and reasoning, to such an extent that it interferes with a person's daily life and activities. - Parkinson's plus syndromes or any other disorder other than idiopathic Parkinson's disease - Moderate to severe dyskinesia is defined as: - Moderate: Dyskinesias impact on activity to the point that the patient usually does not perform some activities or does not usually participate in some social activities during dyskinetic episodes - Severe: Dyskinesia impacts activities to the point that the patient usually does not perform most activities or participate in most social activities during dyskinetic episodes - Patients with severe cardiac disease or congestive heart failure - Severe uncontrolled orthostatic hypotension - Psychosis or psychotic symptoms that would raise concern for safe use of IST, as indicated by domains A (delusions) and B (hallucinations) of the Neuropsychiatric Inventory (NPI), and defined as a score of = 4 on either the A (frequency x severity) or B (frequency x severity) scales of the NPI - Active neoplastic disorder - Current treatment with strong CYP3A4 inhibitors - Current treatment with strong CYP3A4 inducers

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Istradefylline Pill
Istradefylline targets adenosine A2A receptors in the basal ganglia, by inhibiting the indirect pathway It is an adjunctive treatment to carbidopa-levodopa indicated to improve "on" time and decrease off time.

Locations

Country Name City State
United States Georgetown University Hospital McLean Virginia

Sponsors (2)

Lead Sponsor Collaborator
Georgetown University Kyowa Kirin, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To observe the effect of Istradefylline on tremor in PD patients. · Evaluation of changes in MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III tremor score
·· Evaluation of changes in the Movement Disorders Society - United Parkinson's Disease Rating Scale part III tremor score, with the minimum value being 0 and the maximum value being 4 for each sub-scale (rest, kinetic and postural), with a higher score signifying a worse outcome.
8 weeks
Secondary To evaluate the changes in MDS-UPDRS part I (non-motor) in PD patients with tremor. Evaluation of changes in MDS-UPDRS part I (non-motor)
Evaluation of changes in Movement Disorders Society- United Parkinson's Disease Rating Scale Part I (non-motor) with a minimum score being 0 and a maximum score being 52, where a higher score signifies a worse outcome
24 weeks
Secondary To evaluate the changes in MDS-UPDRS II motor symptoms in PD patients with tremor. Evaluation of changes in MDS-UPDRS II motor experiences of daily living (MEDL) score
Evaluation of changes in Movement Disorders Society- United Parkinson's Disease Rating Scale Part II motor experiences of daily living (MEDL) score with a minimum score of 0 and a maximum score of 52 with a higher score signifying a worse outcome.
24 weeks
Secondary To evaluate the changes in cognition, mood and behavior in Parkinson's disease patients treated with Istradefylline. Evaluation of changes in EQ5D
To evaluate the changes in cognition, mood and behavior in Parkinson's disease patients treated with Istradefylline by evaluating the change in score in the EuroQol 5 Dimension 5 Level (EQ5D), with a minimum score of 1 and a maximum score of 15, with a higher value being associated with a worse outcome.
24 weeks
Secondary To evaluate the the Geriatric depression scale (GDS) in PD patients with tremor. - To evaluate the changes in cognition, mood and behavior in Parkinson's disease patients treated with Istradefylline by evaluating the change in score in the Geriatric depression scale (GDS), with a minimum score of 0 and a maximum score of 10, where a higher score signifies a worse outcome. 24 weeks
Secondary To evaluate the effect of Istradefylline on activities of daily living in PD patients with tremor. - To evaluate changes due to adjustments to individual concomitant medications in response to adverse events due to Istradefylline and changes in the Movement Disorders Society- United Parkinson's Disease Rating Scale Part III tremor score. 24 weeks
Secondary To assess the utility of a tremor capturing application such as Mindsquare app. - To assess the utility of a tremor capturing application (Mind-square) to measure tremor severity (amplitude as measured by the average displacement in the Z axis) 24 weeks
Secondary To assess changes in motor impairment using the Right Eye eye- tracking technology. - To assess changes in motor impairment using the Dynamic Vision test, a part of the Right Eye eye-tracking technology, to measure changes in pursuits, fixations and saccades eye movements, which a minimum score of 0 percentile and a maximum score of 100th percentile, with the higher score signifying a better outcome. 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A